oral semaglutide 50 mg oasis 1 nejm 2023 obesity 🚨 25 delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral Semaglutide Treatment Effect in

One Sentence Summary PF-06882961 is an orally administered small molecule that activates the GLP-1 receptor to lower blood glucose in humans

GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly

Two versions circulate: one developed primarily for pigmentation, and a second, broader-acting analog that also affects sexual arousal pathways

Binding of GLP-1 or a synthetic hormone receptor agonist to the GLP-1R on the surface of HEK-Blue GLP-1 cells triggers a signaling cascade leading to the activation of the CRE-binding Protein (CREB) pathway and the subsequent production of SEAP

However, indirect effects of rapid weight lossincluding muscle loss, dehydration, and postural changescan trigger or worsen existing back pain in some patients

EPMA Journal